Westlake Village-based Cynvenio, a developer of molecular analysis technology being used for cancer treatment and management, has launched a new product for cancer diagnostics. The company said it has launched the ClearID Breast Cancer monitoring program, a cancer diagnostics testing program which uses molecular analysis of tumor biomarkers in blood, to help in early detection of breast cancer recurrence. Cynvenio said its blood-based, genomic testing product uses a standard blood sample, and detects the presence of or absence of cancer cells circulating in the blood.
Top NewsThursday, October 3, 2013
Cynvenio Debuts New Cancer Diagnostics Product